Answers are grounded in this paper and cite their sources.
Xanthine oxidoreductase (XOR) inhibitor treatment, which reduces reactive oxygen species (ROS) production and increases adenosine triphosphate (ATP) synthesis, has been reported to improve glycemic control. The possible protective effects of XOR inhibitor treatment on insulin secretory capacity were investigated in patients with type 2 diabetes.
No takes yet. Share an insight, caveat, or question.
Kitamura et al. (2024) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: